IRX-4204 is under clinical development by Io Therapeutics and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IRX-4204’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IRX-4204 overview

IRX-4204 (NRX-4204) is under development for the treatment of solid tumors, HER2+ Breast Cancer, pancreatic cancer, non-small cell lung cancer, aging-related neurodegeneration including Alzheimer's disease, Parkinson's disease, inflammatory arthritides (rheumatoid arthritis), inflammatory bowel disease,  psoriasis, amyotrophic lateral sclerosis, multiple sclerosis, traumatic central nervous injury and transplantation. IRX-4204 is administered orally in the form of a capsule. It is the second generation drug candidate that acts by selectively by targeting pan retinoid X receptor (RXR alpha).
The drug candidate was also under development for the treatment of mesothelioma, asthma, stroke, schizophrenia and castration-resistant prostate cancer and pancreatic cancer.

Io Therapeutics overview

Io Therapeutics is a pharmaceutical company that discovers and develops retinoid and rexinoid small molecules. The company develops therapeutic compounds targeting nuclear receptors for cancer, neurodegenerative and auto-immune diseases including multiple sclerosis. Its pipeline products include IRX4204, an orally available second-generation selective RXR agonist against a variety of human cancers in vitro and in animal models including prostate, breast, pancreas and lung cancer; IRX5183 for the treatment of acute myeloid leukemias and multiple myeloma; and IPX4647. Io Therapeutics is headquartered in Santa Ana, California, the US.

For a complete picture of IRX-4204’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.